Margin gains and an OEM recovery support the growth plan

Margins rise while oncology expands

Merit is executing well on its Continued Growth Initiatives program. Full-year 2025 sales were 1.516 billion dollars, and the momentum carried into 2026. In Q2 2026, non-GAAP operating margin reached an impressive 22.6 percent. The company is clearly finding ways to run more profitably under current leadership.

Growth is also getting a structural lift. Merit has bought useful assets, including View Point Medical in oncology and Biolife assets in cardiac therapies. The Biolife integration is outperforming, with annualized revenue expectations raised to 23 million dollars. The View Point deal, combined with the May 2026 launch of SCOUT MD, expands the addressable breast biopsy market from roughly 400,000 procedures to 1.3 million procedures.

The bear case rests on headwinds that refuse to fade completely. OEM sales jumped 15 percent year over year in Q2, shaking off a steep drop in Q1, but investors still want to see that business maintain a steady mid-to-high single-digit growth rate. Tariffs also remain a headache. The company actually recognized a refund benefit in Q2 but still raised its projected 2026 tariff hit to roughly 16 million dollars due to policy volatility.

The stock deserves credit for margin progress and a cleaner product lineup, especially after fixing a recent Renal supply chain issue. The proof points are appearing, but the 16 million dollar tariff bill and potential hospital pricing pressure keep the story grounded.

Many small tools for serious procedures

Merit makes and sells medical devices used by doctors during interventional, diagnostic, and therapeutic procedures. These are not consumer products. They are tools used in hospitals, clinics, and procedure rooms, often in areas like cardiology, radiology, oncology, critical care, and endoscopy.

The business has two broad revenue buckets. Foundational products are access and enabling tools, and they represented about two-thirds of revenue entering 2026. Therapeutic products treat disease more directly, and they represent the other third. Therapeutic products are where Merit is trying to add more growth through oncology, endoscopy, renal, and cardiac therapies.

This model works well when Merit sells proprietary devices, improves factories, and folds acquired products into its sales force. It can stumble when hospital demand slows, OEM customers reduce inventory, shipping is delayed, tariffs lift costs, or recalls create operational noise.

Where the growth can come from

Two buckets now matter

Merit reports revenue as Foundational and Therapeutic. The mix below uses management baseline disclosures entering 2026.

What could trip the plan

In one breath